<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36613659</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>A Meta-Analysis Study of SOD1-Mutant Mouse Models of ALS to Analyse the Determinants of Disease Onset and Progression.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">216</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24010216</ELocationID><Abstract><AbstractText>A complex interaction between genetic and external factors determines the development of amyotrophic lateral sclerosis (ALS). Epidemiological studies on large patient cohorts have suggested that ALS is a multi-step disease, as symptom onset occurs only after exposure to a sequence of risk factors. Although the exact nature of these determinants remains to be clarified, it seems clear that: (i) genetic mutations may be responsible for one or more of these steps; (ii) other risk factors are probably linked to environment and/or to lifestyle, and (iii) compensatory plastic changes taking place during the ALS etiopathogenesis probably affect the timing of onset and progression of disease. Current knowledge on ALS mechanisms and therapeutic targets, derives mainly from studies involving superoxide dismutase 1 (SOD1) transgenic mice; therefore, it would be fundamental to verify whether a multi-step disease concept can also be applied to these animal models. With this aim, a meta-analysis study has been performed using a collection of primary studies (n = 137), selected according to the following criteria: (1) the studies should employ SOD1 transgenic mice; (2) the studies should entail the presence of a disease-modifying experimental manipulation; (3) the studies should make use of Kaplan-Meier plots showing the distribution of symptom onset and lifespan. Then, using a subset of this study collection (n = 94), the effects of treatments on key molecular mechanisms, as well as on the onset and progression of disease have been analysed in a large population of mice. The results are consistent with a multi-step etiopathogenesis of disease in ALS mice (including two to six steps, depending on the particular SOD1 mutation), closely resembling that observed in patient cohorts, and revealed an interesting relationship between molecular mechanisms and disease manifestation. Thus, SOD1 mouse models may be considered of high predictive value to understand the determinants of disease onset and progression, as well as to identify targets for therapeutic interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ciuro</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Biotechnological Sciences, Physiology Section, University of Catania, 95123 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sangiorgio</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Biotechnological Sciences, Physiology Section, University of Catania, 95123 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leanza</LastName><ForeName>Giampiero</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Preclinical and Translational Imaging Research Centre-IMPRonTE, University of Catania, 95125 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gulino</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8067-697X</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Biotechnological Sciences, Physiology Section, University of Catania, 95123 Catania, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Preclinical and Translational Imaging Research Centre-IMPRonTE, University of Catania, 95125 Catania, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS epidemiology</Keyword><Keyword MajorTopicYN="N">ALS pathogenesis</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">mathematical model</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">mouse</Keyword><Keyword MajorTopicYN="N">superoxide dismutase 1</Keyword><Keyword MajorTopicYN="N">symptom onset</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>8</Day><Hour>1</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36613659</ArticleId><ArticleId IdType="pmc">PMC9820332</ArticleId><ArticleId IdType="doi">10.3390/ijms24010216</ArticleId><ArticleId IdType="pii">ijms24010216</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A., Logroscino G., Hardiman O., Swingler R., Mitchell D., Beghi E., Traynor B.G. Prognostic factors in ALS: A critical review. Amiotroph. Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Rothstein J.D., Kiernan M.C. Advances in treating amyotrophic lateral sclerosis: Insights from pathophysiological studies. Trends Neurosci. 2014;37:433&#x2013;442. doi: 10.1016/j.tins.2014.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.05.006</ArticleId><ArticleId IdType="pubmed">24927875</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman E.L., Goutman S.A., Petri S., Mazzini L., Savelieff M.G., Shaw P.J., Sobue G. Amyotrophic lateral sclerosis. Lancet. 2022;400:1363&#x2013;1380. doi: 10.1016/S0140-6736(22)01272-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01272-7</ArticleId><ArticleId IdType="pubmed">36116464</ArticleId></ArticleIdList></Reference><Reference><Citation>Sever B., Ciftci H., DeMirci H., Sever H., Ocak F., Yulug B., Tateishi H., Tateishi T., Otsuka M., Fujita M., et al. Comprehensive research on past and future therapeutic strategies devoted to treatment of amyotrophic lateral sclerosis. Int. J. Mol. Sci. 2022;23:2400. doi: 10.3390/ijms23052400.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23052400</ArticleId><ArticleId IdType="pmc">PMC8910198</ArticleId><ArticleId IdType="pubmed">35269543</ArticleId></ArticleIdList></Reference><Reference><Citation>Loscalzo J., Barab&#xe1;si A.-L., Silverman E.K. Network Medicine: Complex Systems in Human Disease and Therapeutics. Harvard University Press; Cambridge, MA, USA: 2017.</Citation></Reference><Reference><Citation>Al-Chalabi A., Hardiman O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chi&#xf2; A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D., Freischmidt A. Update on genetics of amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2022;35:672&#x2013;677. doi: 10.1097/WCO.0000000000001093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000001093</ArticleId><ArticleId IdType="pubmed">35942673</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukkipati S.S., Garrett T., Elbasiouny S.M. The vulnerability of spinal motoneurons and soma size plasticity in a mouse model of amyotrophic lateral sclerosis. J. Physiol. 2018;596:1723&#x2013;1745. doi: 10.1113/JP275498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP275498</ArticleId><ArticleId IdType="pmc">PMC5924829</ArticleId><ArticleId IdType="pubmed">29502344</ArticleId></ArticleIdList></Reference><Reference><Citation>Durand J., Amendola J., Bories C., Lamotte d&#x2019;Incamps B. Early abnormalities in transgenic mouse models of amyotrophic lateral sclerosis. J. Physiol. Paris. 2006;99:211&#x2013;220. doi: 10.1016/j.jphysparis.2005.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphysparis.2005.12.014</ArticleId><ArticleId IdType="pubmed">16448809</ArticleId></ArticleIdList></Reference><Reference><Citation>Giusto E., Codrich M., de Leo G., Francardo V., Coradazzi M., Parenti R., Gulisano M., Vicario N., Gulino R., Leanza G. Compensatory changes in degenerating spinal motoneurons sustain functional sparing in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. J. Comp. Neurol. 2020;528:231&#x2013;243. doi: 10.1002/cne.24751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.24751</ArticleId><ArticleId IdType="pubmed">31364764</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulino R., Vicario N., Giunta M.A.S., Spoto G., Calabrese G., Vecchio M., Gulisano M., Leanza G., Parenti R. Neuromuscular plasticity in a mouse model of spinal motoneuronal loss. Int. J. Mol. Sci. 2019;20:1500. doi: 10.3390/ijms20061500.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20061500</ArticleId><ArticleId IdType="pmc">PMC6471664</ArticleId><ArticleId IdType="pubmed">30917493</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulino R., Forte S., Parenti R., Gulisano M. TDP-43 as a modulator of synaptic plasticity in a mouse model of spinal motoneuron degeneration. CNS Neurol. Disord. Drug Targets. 2015;14:55&#x2013;60. doi: 10.2174/1871527314666150116115414.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527314666150116115414</ArticleId><ArticleId IdType="pubmed">25613499</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulino R., Perciavalle V., Gulisano M. Expression of cell-fate determinants and plastic changes after neurotoxic lesion of adult mice spinal cord by cholera toxin-B saporin. Eur. J. Neurosci. 2010;31:1423&#x2013;1434. doi: 10.1111/j.1460-9568.2010.07170.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2010.07170.x</ArticleId><ArticleId IdType="pubmed">20384775</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicario N., Spitale F.M., Tibullo D., Giallongo C., Amorini A.M., Scandura G., Spoto G., Saab M.W., D&#x2019;Aprile S., Alberghina C., et al. Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing. Cell Death Dis. 2021;12:625. doi: 10.1038/s41419-021-03907-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-03907-1</ArticleId><ArticleId IdType="pmc">PMC8209072</ArticleId><ArticleId IdType="pubmed">34135312</ArticleId></ArticleIdList></Reference><Reference><Citation>Armitage P., Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer. 1954;8:1983&#x2013;1989. doi: 10.1038/bjc.1954.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.1954.1</ArticleId><ArticleId IdType="pmc">PMC2410148</ArticleId><ArticleId IdType="pubmed">15599380</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Calvo A., Chi&#xf2; A., Colville S., Ellis C.M., Hardiman O., Heverin M., Howard R.S., Huisman M.H.B., Keren N., et al. Analysis of amyotrophic lateral sclerosis as a multistep process: A population-based modelling study. Lancet Neurol. 2014;13:1108&#x2013;1113. doi: 10.1016/S1474-4422(14)70219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Mazzini L., D&#x2019;Alfonso S., Corrado L., Canosa A., Moglia C., Manera U., Bersano E., Brunetti M., Barberis M., et al. The multistep hypothesis revisited: The role of genetic mutations. Neurology. 2018;91:e635&#x2013;e642. doi: 10.1212/WNL.0000000000005996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005996</ArticleId><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C., Carr&#xec; M.T. Lessons from models of SOD1-linked familial ALS. Trends Mol. Med. 2004;10:393&#x2013;400. doi: 10.1016/j.molmed.2004.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2004.06.009</ArticleId><ArticleId IdType="pubmed">15310460</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>van Damme P., Robberecht W., van den Bosch L. Modelling amyotrophic lateral sclerosis: Progress and possibilities. Dis. Model. Mech. 2017;10:537&#x2013;549. doi: 10.1242/dmm.029058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.029058</ArticleId><ArticleId IdType="pmc">PMC5451175</ArticleId><ArticleId IdType="pubmed">28468939</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Rothstein J.D. Rodent models of amyotrophic lateral sclerosis. Curr. Protoc. Pharmacol. 2015;69:5&#x2013;67. doi: 10.1002/0471141755.ph0567s69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0567s69</ArticleId><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N. Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Neuropathology. 2001;21:82&#x2013;92. doi: 10.1046/j.1440-1789.2001.00361.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1789.2001.00361.x</ArticleId><ArticleId IdType="pubmed">11304046</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S., Nagai M., Aoki M., Komori T., Itoyama Y., Iwata M. Motor neuron disease in transgenic mice with an H46R mutant SOD1 gene. J. Neuropathol. Exp. Neurol. 2007;66:517&#x2013;524. doi: 10.1097/01.jnen.0000263868.84188.3b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000263868.84188.3b</ArticleId><ArticleId IdType="pubmed">17549011</ArticleId></ArticleIdList></Reference><Reference><Citation>Burlando B., Milanese M., Giordano G., Bonifacino T., Ravera S., Blanchini F., Bonanno G. A multistationary loop model of ALS unveils critical molecular interactions involving mitochondria and glucose metabolism. PLoS ONE. 2020;15:e0244234. doi: 10.1371/journal.pone.0244234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244234</ArticleId><ArticleId IdType="pmc">PMC7746301</ArticleId><ArticleId IdType="pubmed">33332476</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbonell F., Iturria-Medina Y., Evans A.C. Mathematical modeling of protein misfolding mechanisms in neurological diseases: A historical overview. Front. Neurol. 2018;9:37. doi: 10.3389/fneur.2018.00037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00037</ArticleId><ArticleId IdType="pmc">PMC5801313</ArticleId><ArticleId IdType="pubmed">29456521</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloret-Villas A., Varusai T.M., Juty N., Laibe C., Le Nov&#xe8;re N., Hermjakob H., Chelliah V. The impact of mathematical modeling in understanding the mechanisms underlying neurodegeneration: Evolving dimensions and future directions. CPT Pharmacomet. Syst. Pharmacol. 2017;6:73&#x2013;86. doi: 10.1002/psp4.12155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.12155</ArticleId><ArticleId IdType="pmc">PMC5321808</ArticleId><ArticleId IdType="pubmed">28063254</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaabi A. Modeling amyotrophic lateral sclerosis progression: Logic in the logit. Cureus. 2022;14:e24887. doi: 10.7759/cureus.24887.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.24887</ArticleId><ArticleId IdType="pmc">PMC9183745</ArticleId><ArticleId IdType="pubmed">35698688</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M., Buratti E., Morselli E., Criollo A. Autophagy and its impact on neurodegenerative diseases: New roles for TDP-43 and C9orf72. Front. Mol. Neurosci. 2017;10:170. doi: 10.3389/fnmol.2017.00170.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00170</ArticleId><ArticleId IdType="pmc">PMC5447761</ArticleId><ArticleId IdType="pubmed">28611593</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland D.S., Liu J., She Y., Goad B., Maragakis N.J., Kim B., Erickson J., Kulik J., DeVito L., Psaltis G., et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) Proc. Natl. Acad. Sci. USA. 2002;99:1604&#x2013;1609. doi: 10.1073/pnas.032539299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.032539299</ArticleId><ArticleId IdType="pmc">PMC122237</ArticleId><ArticleId IdType="pubmed">11818550</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Agar J.N., Taylor J.N., Minotti S., Durham H.D. Focal dysfunction of the proteasome: A pathogenic factor in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2004;89:1325&#x2013;1335. doi: 10.1111/j.1471-4159.2004.02453.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02453.x</ArticleId><ArticleId IdType="pubmed">15189335</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S., Kollewe K., Fahlbusch M., Zapf A., Dengler R., Krampfl K., Petri S. Onset and spreading patterns of upper and lower motor neuron symptoms in amyotrophic lateral sclerosis. Muscle Nerve. 2011;43:636&#x2013;642. doi: 10.1002/mus.21936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21936</ArticleId><ArticleId IdType="pubmed">21484822</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniecka Z., Polymenidou M. From nucleation to widespread propagation: A prion-like concept for ALS. Virus Res. 2015;207:94&#x2013;105. doi: 10.1016/j.virusres.2014.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2014.12.032</ArticleId><ArticleId IdType="pubmed">25656065</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L., Plotkin S.S., Yerbury J.J., Cashman N.R. Prion-like propagation of protein misfolding and aggregation in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2019;12:262. doi: 10.3389/fnmol.2019.00262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00262</ArticleId><ArticleId IdType="pmc">PMC6838634</ArticleId><ArticleId IdType="pubmed">31736708</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nch C., O&#x2019;Brien J., Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc. Natl. Acad. Sci. USA. 2011;108:3548&#x2013;3553. doi: 10.1073/pnas.1017275108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1017275108</ArticleId><ArticleId IdType="pmc">PMC3048161</ArticleId><ArticleId IdType="pubmed">21321227</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson T.D., Sher R.B., Blankenhorn E.A., Alexander G., Deitch J.S., Kunst C.B., Maragakis N., Cox G. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: A window of opportunity in the search for genetic modifiers. Amyotroph. Lateral. Scler. 2011;12:79&#x2013;86. doi: 10.3109/17482968.2010.550626.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.550626</ArticleId><ArticleId IdType="pubmed">21241159</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino M., Papa S., Crippa V., Nardo G., Peviani M., Cheroni C., Trolese M.C., Lauranzano E., Bonetto V., Poletti A., et al. Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis. Neurobiol. Aging. 2015;36:492&#x2013;504. doi: 10.1016/j.neurobiolaging.2014.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.06.026</ArticleId><ArticleId IdType="pubmed">25085783</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Trolese M.C., Tortarolo M., Vallarola A., Freschi M., Pasetto L., Bonetto V., Bendotti C. New insights on the mechanisms of disease course variability in ALS mutant SOD1 mouse models. Brain Pathol. 2016;26:237&#x2013;247. doi: 10.1111/bpa.12351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12351</ArticleId><ArticleId IdType="pmc">PMC8029191</ArticleId><ArticleId IdType="pubmed">26780365</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfohl S.R., Halicek M.T., Mitchell C.S. Characterization of the contribution of genetic background and gender to disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis: A meta-analysis. J. Neuromuscul. Dis. 2015;2:137&#x2013;150. doi: 10.3233/JND-140068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-140068</ArticleId><ArticleId IdType="pmc">PMC4652798</ArticleId><ArticleId IdType="pubmed">26594635</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A., Kiernan M., Mitsumoto H., Swash M. Amyotrophic lateral sclerosis: A long preclinical period? J. Neurol. Neurosurg. Psychiatry. 2014;85:1232&#x2013;1238. doi: 10.1136/jnnp-2013-307135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-307135</ArticleId><ArticleId IdType="pubmed">24648037</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zundert B., Izaurieta P., Fritz E., Alvarez F.J. Early pathogenesis in the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J. Cell. Biochem. 2012;113:3301&#x2013;3312. doi: 10.1002/jcb.24234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.24234</ArticleId><ArticleId IdType="pmc">PMC3886915</ArticleId><ArticleId IdType="pubmed">22740507</ArticleId></ArticleIdList></Reference><Reference><Citation>Klus P., Cirillo D., Botta Orfila T., Tartaglia G.G. Neurodegeneration and cancer: Where the disorder prevails. Sci. Rep. 2015;5:15390. doi: 10.1038/srep15390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep15390</ArticleId><ArticleId IdType="pmc">PMC4615981</ArticleId><ArticleId IdType="pubmed">26493371</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke B.E., Patani R. The microglial component of amyotrophic lateral sclerosis. Brain. 2020;143:3526&#x2013;3539. doi: 10.1093/brain/awaa309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa309</ArticleId><ArticleId IdType="pmc">PMC7805793</ArticleId><ArticleId IdType="pubmed">33427296</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B., Zhao W., Beers D.R., Henkel J.S., Appel S.H. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp. Neurol. 2012;237:147&#x2013;152. doi: 10.1016/j.expneurol.2012.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.06.011</ArticleId><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff J.R., Simpson E.P., Appel S.H. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr. Opin. Neurol. 2018;31:635&#x2013;639. doi: 10.1097/WCO.0000000000000599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>KEGG: Kyoto Encyclopedia of Genes and Genomes/Amyotrophic Lateral Sclerosis&#x2014;Reference Pathway.  [(accessed on 10 December 2022)].  Available online:  https://www.kegg.jp/pathway/map=map05014&amp;keyword=ALS.</Citation></Reference><Reference><Citation>Tann J.Y., Wong L.-W., Sajikumar S., Ib&#xe1;&#xf1;ez C.F. Abnormal TDP-43 function impairs activity-dependent BDNF secretion, synaptic plasticity, and cognitive behavior through altered Sortilin splicing. EMBO J. 2019;38:e100989. doi: 10.15252/embj.2018100989.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2018100989</ArticleId><ArticleId IdType="pmc">PMC6396160</ArticleId><ArticleId IdType="pubmed">30692134</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulino R., Parenti R., Gulisano M. Novel mechanisms of spinal cord plasticity in a mouse model of motoneuron disease. Biomed. Res. Int. 2015;2015:654637. doi: 10.1155/2015/654637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/654637</ArticleId><ArticleId IdType="pmc">PMC4433663</ArticleId><ArticleId IdType="pubmed">26064939</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulino R., Gulisano M. Involvement of brain-derived neurotrophic factor and sonic hedgehog in the spinal cord plasticity after neurotoxic partial removal of lumbar motoneurons. Neurosci. Res. 2012;73:238&#x2013;247. doi: 10.1016/j.neures.2012.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2012.04.010</ArticleId><ArticleId IdType="pubmed">22579680</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda-Lauren&#xe7;o C., Ribeiro-Rodrigues L., Fonseca-Gomes J., Tanqueiro S.R., Belo R.F., Ferreira C.B., Rei N., Ferreira-Manso M., de Almeida-Borlido C., Costa-Coelho T., et al. Challenges of BDNF-based therapies: From common to rare diseases. Pharmacol. Res. 2020;162:105281. doi: 10.1016/j.phrs.2020.105281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.105281</ArticleId><ArticleId IdType="pubmed">33161136</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>